Company Name
HAWK Biosystems
Activity
HAWK Biosystems has developed and patented a technology that provides deeper insight into how treatments—primarily for cancer—actually work. Their tool enables more detailed analysis of patient biopsies and how cells respond to specific drugs. This helps design more effective, personalized therapies and accelerates the development of new medicines.
CIF
B95827903
Sector
Biotechnology
Address
Astondo Bidea 612, mod 02 - Derio
EPM Joining Date
27/03/2025
Creation Date
22/01/2016
Founders Peter J. Parker Francis Crick Antonio Parente Antonio Ferrer
Auditor
Gabino Mesa Auditores, S.L.P.
Investors email contact
contact@hawkbiosystems.com
Company profile
Biotechnology
At HAWK Biosystems, we are committed to innovation in precision medicine, and being part of BME’s Pre-Market Environment represents a strategic step in our growth. This program provides us with access to a network of investors and capital market experts, facilitating new opportunities to consolidate our development and accelerate the expansion of our QF-Pro® technology. We believe that the stock market route is a key alternative to strengthen our impact on the biomedical industry and to continue advancing our mission to transform cancer treatment.
Relevant data
| (thousand of Euros) | 2024 | 2025* | 2026* | 2027* |
|---|---|---|---|---|
| Net worth | 3.232 | 5.231 | 8.640 | 10.927 |
| Net business turnover | 302 | 880 | 4.170 | 12.740 |
| Financial debt | 664 | 180 | 200 | 250 |
| Ebitda | 123 | -30 | 610 | 3.130 |
| Net Profit | 76 | -85 | 409 | 2.288 |
| Average number of employees | 18 | 19 | 22 | 35 |
| * Proyection | ||||
Investment Rounds
| Date | Status | Amount | Minimum Ticket |
|---|---|---|---|
| 01-01-2025 | Open | 2.000.000 | 100000,00 |
Business Model
HAWK Biosystems generates revenue through the sale of its analysis systems, licensing of its proprietary technology, and specialized services for the biopharmaceutical industry. It partners in clinical trials to help optimize therapies and improve patient selection. The business model combines hardware, software, and biomedical expertise to increase treatment success.
Competitive advantage
HAWK Biosystems offers a unique, patented technology that detects key protein functions directly in tumor biopsies. This reveals how cells interact and how the immune system responds to treatment—insights that traditional methods cannot provide. It delivers crucial functional and spatial information to better predict therapeutic success.
Scalability
HAWK Biosystems has a highly scalable business model, combining modular technology, automation, and hybrid revenue streams. Its platform applies across multiple cancer types and stages of drug development. It operates within the massive global market of immuno-oncology and personalized medicine, valued in the hundreds of billions. This positions HAWK for rapid growth and strong profitability.
